TOP TIERMARKET NEWSWIRE

News & sentiment

EUPRAXIA PHARMACEUTI Equity (EPRX) — News & AI sentiment

EUPRAXIA PHARMACEUTI Equity (EPRX) news roundup. 8 stories in the past week, 14 over 30 days. Average 30-day sentiment is 50.5/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

8

avg sentiment 48.9/100

30d stories

14

avg sentiment 50.5/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

EPRX news in the last 24 hours, 7 days, 30 days and 90 days

How much EPRX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	EPRX stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	8	48.9/100	EPRX headlines →
Last 30 days	14	50.5/100	EPRX headlines →
Last 90 days	29	55.1/100	EPRX headlines →

Latest stories on EPRX

Eupraxia Pharmaceuticals price target raised to $16 from $11 at H.C. Wainwright

The Fly64 · neutralanalyst

3d ago

Eupraxia Pharmaceuticals reports Q3 results

Seeking Alpha42 · neutralearnings

3d ago

Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program

GlobeNewswire31 · bearishgeneral

3d ago

Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program

StockTitan28 · bearishgeneral

3d ago

Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results

GlobeNewswire50 · neutralearnings

3d ago

Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results

StockTitan50 · neutralearnings

3d ago

Eupraxia Pharmaceuticals initiated with an Outperform at RBC Capital

The Fly63 · neutralanalyst

5d ago

RBC Capital initiates Eupraxia Pharmaceuticals stock with outperform rating

Investing.com Analyst Ratings63 · neutralanalyst

5d ago

Eupraxia Pharmaceuticals: Promising Science, But Competition And Valuation Limit Upside

Seeking Alpha38 · neutralanalyst

Oct 22

Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day

Business Insider53 · neutralproduct/pr

Oct 22

Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day

GlobeNewswire53 · neutralproduct/pr

Oct 22

Oppenheimer reiterates Eupraxia stock rating on EoE data

Investing.com Analyst Ratings50 · neutralanalyst

Oct 20

Eupraxia Pharmaceuticals reaches enrollment target for RESOLVE study

The Fly61 · neutralproduct/pr

Oct 15

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

GlobeNewswire61 · neutralproduct/pr

Oct 15

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

GlobeNewswire53 · neutralproduct/pr

Oct 9

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

Business Insider52 · neutralproduct/pr

Oct 9

Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

GlobeNewswire63 · neutralgeneral

Oct 7

Wainwright reiterates Eupraxia stock rating on positive trial data

Investing.com Analyst Ratings63 · neutralanalyst

Oct 1

Eupraxia announces data from Phase 1b/2a RESOLVE study of EP-104GI

The Fly63 · neutralproduct/pr

Sep 30

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Business Insider63 · neutralproduct/pr

Sep 30

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

GlobeNewswire63 · neutralproduct/pr

Sep 30

Wedbush bullish on Eupraxia Pharmaceuticals, initiates with an Outperform

The Fly61 · neutralanalyst

Sep 24

Wedbush initiates Eupraxia Pharmaceuticals stock with Outperform rating

Investing.com Analyst Ratings61 · neutralanalyst

Sep 24

Eupraxia Pharmaceuticals initiated with an Outperform at Wedbush

The Fly61 · neutralanalyst

Sep 24

Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice

Yahoo Top67 · bullishproduct/pr

Sep 12

Open EPRX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →